@YakovBk You know, that’s a good question. Some thoughts (remember I’m biased in the pro BIORA direction that they are acting in good faith)
I think they do not disclose prices because their businesses are competitive and sensitive to pricing.
$BIOR I remember the conversations long ago where questions were being asked during the sell off of assets if preecludia was sold off. It appears that BIORA still owns Preecludia and is licensing it out to their old subsidiary which was bought by Northwest pathology.
@Baccurate Thanks! Very kind! I’m doing good. Holding my shares tight and still buying. They are trying to survive at the moment, My plan is to continue to by them up as my timeline to sell is in 2026 and later
I’m glad Elon Musk took over Twitter. Some of the headlines show that 70% of the workers resigned and Twitter is still running. This really makes you wonder what those people were doing in the first place. I hope they can find somewhere else to be more productive to society
$BIOR
1. We should be hearing about the Q3 FDA decision regarding the recommended path forward for the DDS ulcerative colitis trials.
2. Data readouts from their studies which may shed light on the OBDS partnerships.
An... https://t.co/92qXTlA7kH
@BubbleTeaExtra I think it’s definitely a risk we have to accept. My own thoughts are that BIOR will receive further funding after their progress from the OBDS & DDS programs.
Ionis most likely does want BIOR to stay and could contribute some cash to the OBDS program.
$BIOR one thing about the digestive tech industry is that it is already becoming widely accepted . Look at the endoscopy industry, they use a smart pill with a camera. I’ve got industry contacts who are praising the use of... https://t.co/W7eNA39kkp